DDW Roundup
ImmusanT Inc., of Cambridge, Mass., presented Phase I data showing that Nexvax2 was well tolerated and induced a T-cell response confirming bioactivity in HLA-DQ2 genotype celiac disease patients. Nexvax2 is a therapeutic vaccine that combines three peptides that elicit an immune response in patients with the immune recognition gene HLA-DQ2. A Phase IIa trial is expected to begin within a year.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.